CTL Medical has secured US Food and Drug (FDA) clearance to market its new Matisse titanium anterior cervical interbody fusion (ACIF) cage implant with the company’s TiCro surface, used in the practice of spine fusion surgery.
According to a company release, the Matisse technology offers 200% greater endplate contact surface area, as well as bone-conforming geometry for increased mechanical locking at the cage and bone interface. The implant includes a tapered leading edge designed for easy insertion, and a large graft area. The device is available in a variety of sizes and configurations to accommodate variations in vertebral levels and patient anatomy.
“Countless engineering hours and research and development resources went in to developing CTL Medical’s patent pending TiCro surface technology, which was designed to expand our current portfolio, advance fusion technologies, and offer spine surgeons numerous surgical advantages,” states Danny Chon, president & chief executive officer of CTL Medical. “The Matisse system includes streamlined instrumentation and a variety of footprints, heights and lordotic profiles to accommodate variations in patient anatomy.”
Matisse is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one-disc level. The system is to be used with supplemental fixation.